Antifungal and marker effects of Talisia esculenta lectin on Microsporum canis in vitro

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Aims: The purpose of this study was to demonstrate the usefulness of lectin obtained from Talisia esculenta (TEL) seeds as a tool to recognize and study Microsporum canis. For this purpose, we investigated the antifungal and marker action of this lectin and the relationship of these effects with the presence of carbohydrates on the structure of this fungus. Methods and Results: The in vitro antifungal activity of TEL was analysed by broth microdilution assay. In addition, TEL was assessed against the arthroconidia present on hairs obtained from infected dogs and cats. The affinity of fluorescein isothiocyanate (FITC)-labelled TEL for macroconidia and arthroconidia of M. canis was also tested. The effects of TEL on the growth of the M. canis strains began with 0 center dot 125 mg ml-1, and 100% inhibition was obtained with a concentration of 2 mg ml-1. The addition of carbohydrates, especially N-acetyl-glucosamine and d-mannose, inhibited these antifungal effects. TEL was able to inhibit the growth of arthroconidial chitin-rich forms of M. canis obtained from hairs of infected animals and strains cultured in Sabouraud agar. FITC-labelled TEL efficiently marked macroconidial and arthroconidial forms of M. canis, as shown by fluorescent microscopy. Conclusions: These results show that the inhibitory effects of TEL on M. canis growth may be related to the interaction of lectin with the carbohydrates present at the micro-organism's surface, mainly d-mannose and N-acetyl-glucosamine. Significance and Impact of the Study: Talisia esculenta can be used as an important tool in the biochemical study of M. canis or as a molecule to recognize this dermatophyte in infected tissue.107620632069Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)FUNCAP (Ceara State Research Support Foundation) [9836/06]Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)CNPq [475724/2006-2]FUNCAP (Ceara State Research Support Foundation) [9836/06

Especificidades do patenteamento no setor farmacêutico: modalidades e aspectos da proteção intelectual Specificities of patent protection in the pharmaceutical industry: modalities and traits of intellectual property

As formas de proteção das invenções no setor farmacêutico apontam para estratégias de perpetuação da proteção patentária. Com base em uma revisão bibliográfica mostrou-se as especificidades do patenteamento no setor, perpassando por um breve histórico sobre a concessão de patentes farmacêuticas no Brasil, uma abordagem sobre invenções patenteáveis e não-patenteáveis, e pelas modalidades e aspectos da proteção patentária que visam à extensão do monopólio temporário conferido pela patente. Dentre essas estratégias estão as patentes direcionadas a polimorfos e isômeros ópticos de fármacos; combinações de fármacos e segundo uso médico, cada vez mais presentes nas reivindicações dos pedidos de privilégio de invenção das indústrias farmacêuticas. O objetivo do trabalho é mostrar algumas especificidades dos pedidos de patente farmacêuticas, de modo a contribuir para a formação de expertise na área e para a discussão sobre o impacto da ampliação dos escopos de proteção das patentes. Conclui-se que se por um lado a tendência de escopos de proteção mais permissivos pode desvelar oportunidades para os inventores nacionais, por outro, pode ser danosa para uma política de acesso a medicamentos.<br>Different forms of protection for inventions in the pharmaceutical industry point to strategies for the perpetuation of patent protection. Based on a literature review showing the specificities of patenting in the industry, the article provides a brief history of drug patents in Brazil, a discussion of patentable and non-patentable inventions, and the modalities and traits of patent protection that aim to extend the temporary monopoly granted under the patent. Such strategies include patents targeting polimorphs and optical isomers of drugs and drug combinations and specific clinical preparations, increasingly present in the drug patent claims filed by pharmaceutical companies. The study's objective is to discuss the specificities of drug patent claims in order to help develop expertise in the area and discuss the impact of expanding the scope of patent protection. In conclusion, while the tendency to expand towards more a permissive protective scope could produce opportunities for Brazilian national inventors, it could also be harmful to a policy for access to medicines